Literature DB >> 29277338

Hypothalamic abnormalities: Growth failure due to defects of the GHRH receptor.

Manuel H Aguiar-Oliveira1, Caridad Davalos2, Viviane C Campos3, Luiz A Oliveira Neto4, Cindi G Marinho3, Carla R P Oliveira3.   

Abstract

Several acquired or congenital hypothalamic abnormalities may cause growth failure (GF). We described two of these congenital abnormalities. First, a case of CHARGE syndrome, an epigenetic disorder mostly caused by heterozygous mutations in the gene encoding CHD7, a chromatin remodeling protein, causing several malformations, some life-threatening, with additional secondary hypothalamus-hypophyseal dysfunction, including GF. Second, a cohort of individuals with genetic isolated severe GH deficiency (IGHD), due to a homozygous mutation in the GH-releasing hormone (GHRH) receptor gene described in Itabaianinha County, in northeast Brazil. In this IGHD, with marked reduction of serum concentrations of IGF-I, and an up regulation of IGF-II, GF is the principal finding in otherwise normal subjects, with normal quality of life and longevity. This IGHD may unveil the effects of GHRH, pituitary GH and IGF-I, IGF-II and local GH and growth factor on the size and function of body and several systems. For instance, anterior pituitary hypoplasia, and impairment of the non-REM sleep may be due to GHRH resistance. Proportionate short stature, doll facies, high-pitched pre-pubertal voice, and reduced muscle mass reflect the lack of the synergistic effect of pituitary GH and IGF-I in bones and muscles. Central adiposity may be due to a direct effect of the lack of GH. Brain, eyes and immune system may also involve IGF-II and local GH or growth factors. A concept of physiological hierarchy controlling body size and function by each component of the GH system may be drawn from this model.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  GH; GHRH; GHRHR; IGF-I; IGF-II

Mesh:

Substances:

Year:  2017        PMID: 29277338     DOI: 10.1016/j.ghir.2017.12.011

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  2 in total

Review 1.  Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways.

Authors:  Haim Werner; Lena Lapkina-Gendler; Laris Achlaug; Karthik Nagaraj; Lina Somri; Danielle Yaron-Saminsky; Metsada Pasmanik-Chor; Rive Sarfstein; Zvi Laron; Shoshana Yakar
Journal:  Cells       Date:  2019-06-15       Impact factor: 6.600

2.  Characterization of Two Mouse Chd7 Heterozygous Loss-of-Function Models Shows Dysgenesis of the Corpus Callosum and Previously Unreported Features of CHARGE Syndrome.

Authors:  Stephan C Collins; Valerie E Vancollie; Anna Mikhaleva; Christel Wagner; Rebecca Balz; Christopher J Lelliott; Binnaz Yalcin
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.